Last reviewed · How we verify
metronidazole and doxycycline
metronidazole and doxycycline is a Antibiotic combination Small molecule drug developed by Hospital de Clinicas de Porto Alegre. It is currently FDA-approved for Mixed aerobic-anaerobic bacterial infections, Intra-abdominal infections, Pelvic inflammatory disease.
Metronidazole and doxycycline together provide broad-spectrum antimicrobial coverage by disrupting bacterial DNA synthesis and protein production.
Metronidazole and doxycycline together provide broad-spectrum antimicrobial coverage by disrupting bacterial DNA synthesis and protein production. Used for Mixed aerobic-anaerobic bacterial infections, Intra-abdominal infections, Pelvic inflammatory disease.
At a glance
| Generic name | metronidazole and doxycycline |
|---|---|
| Sponsor | Hospital de Clinicas de Porto Alegre |
| Drug class | Antibiotic combination |
| Target | Bacterial DNA (metronidazole); bacterial 30S ribosome (doxycycline) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Metronidazole is a nitroimidazole that generates reactive oxygen species to damage bacterial DNA, particularly effective against anaerobes. Doxycycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Together, they provide synergistic coverage against mixed aerobic and anaerobic infections.
Approved indications
- Mixed aerobic-anaerobic bacterial infections
- Intra-abdominal infections
- Pelvic inflammatory disease
- Periodontal infections
Common side effects
- Nausea
- Diarrhea
- Metallic taste (metronidazole)
- Photosensitivity (doxycycline)
- Esophageal irritation
- Vaginal candidiasis
Key clinical trials
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- Fecal Molecular Susceptibility-guided Hp First-line Therapy (PHASE4)
- Fecal Molecular Susceptibility-guided Hp Rescue Therapy (PHASE4)
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Lesion Sterilization And Tissue Repair Versus Zinc Oxide And Eugenol For Treatment of Necrotic Primary Molars (PHASE2, PHASE3)
- To Evaluate the Effects of Systemic Probiotics & Antibiotics and Local Application of Antibiotics As an Adjuvant to NSPT (NA)
- A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection (PHASE4)
- Efficacy and Safety of Fuke Qianjin Capsule in Patients With Pelvic Inflammatory Diseases (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metronidazole and doxycycline CI brief — competitive landscape report
- metronidazole and doxycycline updates RSS · CI watch RSS
- Hospital de Clinicas de Porto Alegre portfolio CI
Frequently asked questions about metronidazole and doxycycline
What is metronidazole and doxycycline?
How does metronidazole and doxycycline work?
What is metronidazole and doxycycline used for?
Who makes metronidazole and doxycycline?
What drug class is metronidazole and doxycycline in?
What development phase is metronidazole and doxycycline in?
What are the side effects of metronidazole and doxycycline?
What does metronidazole and doxycycline target?
Related
- Drug class: All Antibiotic combination drugs
- Target: All drugs targeting Bacterial DNA (metronidazole); bacterial 30S ribosome (doxycycline)
- Manufacturer: Hospital de Clinicas de Porto Alegre — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Mixed aerobic-anaerobic bacterial infections
- Indication: Drugs for Intra-abdominal infections
- Indication: Drugs for Pelvic inflammatory disease